T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies | DelveInsight

The T-cell malignancies market is driven by the rising incidence of these cancers, advancements in treatment options, and strategic partnerships within the biopharma industry. Increasing regulatory approvals for innovative therapies and a growing focus on R&D are fostering rapid innovation, while geographic markets like North America and Asia-Pacific are experiencing substantial growth. Technological advancements in diagnostics are also enhancing the ability to identify and treat T-cell malignancies effectively, contributing to the overall expansion of the market.

LAS VEGAS, Oct. 30, 2024 /PRNewswire/ — DelveInsight’s ‘T-cell Malignancies Pipeline Insight 2024‘ report provides comprehensive global coverage of pipeline T-cell malignancy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the T-cell malignancies pipeline domain.

Key Takeaways from the T-cell Malignancies Pipeline Report

DelveInsight’s T-cell malignancies pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for T-cell malignancy treatment.
Key T-cell malignancy companies such as Corvus Pharmaceuticals, Bristol-Myers Squibb, Kymera Therapeutics, neoX Biotech, Jiangsu Hengrui Medicine, Soligenix, Equillium, Janssen Biotech, Ono Pharmaceutical, Artiva Biotherapeutics, Dialectic Therapeutics, Nutcracker Therapeutics, Step Pharma, March Biosciences, Astex Pharmaceuticals, Bio-Path Holdings, MorphoSys, PersonGen BioTherapeutics, Xenothera, Sichuan Baili Pharmaceutical/SystImmune, and others are evaluating new T-cell malignancy drugs to improve the treatment landscape.
Promising T-cell malignancies pipeline therapies such as Soquelitinib, Golcadomide, KT-333, NXD02, SHR-2554, Hypericin, EQ-101, Daratumumab, ONO-4685, AB-205, DT-2216, NTX-565, Dencatistat, MB 105, ASTX 660, BP1002, CPI 0209, UTAA13γδT, LIS1, GNC-038, and others are under different phases of T-cell Malignancies clinical trials.
In September 2024, Corvus Pharmaceuticals announced that it had initiated a registrational Phase III clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).
In August 2024, Corvus Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to soquelitinib for the treatment of adult patients with relapsed or refractory peripheral T cell lymphoma (PTCL) after at least two lines of systemic therapy.
In August 2024, Viracta Therapeutics reported positive Phase II NAVAL-1 trial results from Stages 1 and 2 of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort.
In August 2024, SELLAS Life Sciences Group announced that the European Medicines Agency (EMA) had granted Orphan Drug Designation (ODD) for SLS009, a novel, and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL).
In June 2024, Kymera Therapeutics shared new clinical data from its ongoing KT-333 Phase I trial. KT-333, a first-in-class, potent, highly selective, heterobifunctional small molecule degrader of STAT3, demonstrated antitumor responses in hematological malignancies with high unmet need, including relapsed/refractory classic Hodgkin’s lymphoma (cHL), cutaneous T-cell lymphoma (CTCL), and NK-cell lymphoma, at doses that were well-tolerated. The data were presented at the European Hematology Association (EHA) Annual Meeting.
In May 2024, Soligenix announced that the results of its compatibility study evaluating HyBryte (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in the Journal of the European Academy of Dermatology & Venereology (JEADV) Clinical Practice.
In November 2023, March Biosciences announced that it had received a notice of award for a major competitive grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to help support continued clinical development of its innovative chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed and refractory CD5 positive T-cell cancers. The approximately $13.4 million product development award is intended to support March Bio’s upcoming Phase II clinical trial of MB-105 for the treatment of relapsed and refractory T-cell lymphomas.

Request a sample and discover the recent advances in T-cell malignancy treatment drugs @ T-cell Malignancies Pipeline Report

The T-cell malignancies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage T-cell malignancy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the T-cell malignancies clinical trial landscape.

T-cell Malignancies Overview

T-cell malignancies are a diverse group of cancers that originate from T-lymphocytes, which are a type of white blood cell crucial for the immune system. These malignancies can manifest in various forms, including T-cell leukemia, T-cell lymphoma, and peripheral T-cell lymphoma. They often arise from the malignant transformation of mature T-cells or their precursors, leading to uncontrolled proliferation and accumulation of abnormal T-cells in the blood, lymphatic system, or other tissues. Symptoms can vary widely depending on the specific type and stage of the disease, but they often include enlarged lymph nodes, fever, night sweats, and weight loss.

Diagnosis and treatment of T-cell malignancies can be complex due to the heterogeneous nature of these diseases. Advanced diagnostic techniques, such as flow cytometry, immunohistochemistry, and genetic profiling, are crucial for accurate classification and staging. Treatment strategies may include chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation. The prognosis for patients with T-cell malignancies varies based on the specific type, stage of the disease, and response to treatment, making personalized treatment approaches essential for improving outcomes.

Find out more about T-cell malignancies treatment drugs @ Drugs for T-cell Malignancies Treatment

A snapshot of the T-cell Malignancies Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Soquelitinib	Corvus Pharmaceuticals	Phase III	Emt protein-tyrosine kinase inhibitors	Oral
MB 105	March Biosciences	Phase II	T lymphocyte replacements	Intravenous
Golcadomide	Bristol-Myers Squibb	Phase II	CRBN protein modulators; Ubiquitin protein ligase modulators	Oral
KT-333	Kymera Therapeutics	Phase I	STAT3 transcription factor degraders	Intravenous
ONO 4685	Ono Pharmaceutical	Phase I	CD3 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants	Intravenous

Learn more about the emerging T-cell malignancies pipeline therapies @ T-cell Malignancies Clinical Trials

T-cell Malignancies Therapeutics Assessment

The T-cell malignancies pipeline report proffers an integral view of the T-cell malignancies emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the T-cell Malignancies Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Intravenous, Subcutaneous, Oral, Intramuscular
Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide
Therapeutics Assessment By Mechanism of Action: Angiogenesis inhibitors, Colony-stimulating factor inhibitors, Coronavirus 3C-like proteinase inhibitors, Endopeptidase Clp inhibitors, Focal adhesion protein tyrosine kinase inhibitors, Lyn protein-tyrosine kinase inhibitors, Macrophage colony-stimulating factor receptor modulators, Mast cell inhibitors, Platelet-derived growth factor receptor antagonists, Protein tyrosine kinase inhibitors, Proto-oncogene protein c-fyn modulators, Proto-oncogene protein c-kit inhibitors, Type 3 fibroblast growth factor receptor antagonists, Emt protein-tyrosine kinase inhibitors, CRBN protein modulators, Ubiquitin protein ligase modulators, STAT3 transcription factor degraders, Bcl-X protein degraders
Key T-cell Malignancies Companies: Corvus Pharmaceuticals, Bristol-Myers Squibb, Kymera Therapeutics, neoX Biotech, Jiangsu Hengrui Medicine, Soligenix, Equillium, Janssen Biotech, Ono Pharmaceutical, Artiva Biotherapeutics, Dialectic Therapeutics, Nutcracker Therapeutics, Step Pharma, March Biosciences, Astex Pharmaceuticals, Bio-Path Holdings, MorphoSys, PersonGen BioTherapeutics, Xenothera, Sichuan Baili Pharmaceutical/SystImmune, and others
Key T-cell Malignancies Pipeline Therapies: Soquelitinib, Golcadomide, KT-333, NXD02, SHR-2554, Hypericin, EQ-101, Daratumumab, ONO-4685, AB-205, DT-2216, NTX-565, Dencatistat, MB 105, ASTX 660, BP1002, CPI 0209, UTAA13γδT, LIS1, GNC-038, and others

Dive deep into rich insights for new drugs for T-cell malignancies treatment, visit @ T-cell Malignancies Drugs

Table of Contents

1.	T-cell Malignancies Pipeline Report Introduction
2.	T-cell Malignancies Pipeline Report Executive Summary
3.	T-cell Malignancies Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	T-cell Malignancies Clinical Trial Therapeutics
6.	T-cell Malignancies Pipeline: Late-Stage Products (Pre-registration)
7.	T-cell Malignancies Pipeline: Late-Stage Products (Phase III)
8.	T-cell Malignancies Pipeline: Mid-Stage Products (Phase II)
9.	T-cell Malignancies Pipeline: Early-Stage Products (Phase I)
10.	T-cell Malignancies Pipeline Therapeutics Assessment
11.	Inactive Products in the T-cell Malignancies Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the T-cell Malignancies Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the T-cell malignancies pipeline therapeutics, reach out @ T-cell Malignancies Treatment Drugs

Related Reports

T-cell malignancies Epidemiology

T-cell malignancies Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the T-cell malignancies epidemiology trends.

B-Cell Lymphoma Market

B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others.

Diffuse Large B-Cell Lymphoma Pipeline

Diffuse Large B-Cell Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, among others.

Diffuse Large B-Cell Lymphoma Market

Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us
Shruti Thakur

[email protected]

+14699457679

www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP